Research programme: hepatitis C virus NS3 protein inhibitors - Eli Lilly and Company
Alternative Names: Hepatitis C virus protease inhibitors; LY-514962; LY-526181Latest Information Update: 29 Feb 2008
At a glance
- Originator Eli Lilly and Company
- Class Small molecules
- Mechanism of Action Hepatitis C virus NS3 protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Hepatitis C
Most Recent Events
- 21 Jun 2004 Preclinical trials in Hepatitis C treatment in USA (unspecified route)